Journal of nephrology
-
Journal of nephrology · Jan 2009
Randomized Controlled TrialRosuvastatin in hemodialysis: short-term effects on lipids and C-reactive protein.
Patients on regular hemodialysis present high cardiovascular mortality. Uremic dyslipidemia and inflammation take part in the etiology of atherosclerosis. Rosuvastatin calcium has not been studied in patients on dialysis to date. We sought to evaluate the results of rosuvastatin therapy regarding lipids, lipoproteins and a marker of inflammation in hemodialysis patients. ⋯ Rosuvastatin calcium at 10 mg/day was effective in lowering total cholesterol, LDL cholesterol, non-HDL cholesterol and hs-CRP in hemodialysis patients.